- Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
-
Sang Youn Hwang, Sun Mi Lee, Jeong Woo Lim, Gi Jung Jeon, Hye Won Lee
-
J Liver Cancer. 2021;21(2):177-180. Published online September 30, 2021
-
DOI: https://doi.org/10.17998/jlc.2021.09.10
-
-
 Abstract
 PDF
- Sorafenib is the oldest first line systemic treatment in patients with advanced hepatocellular
carcinoma (HCC) and has been used exclusively for nearly 10 years. The superiority of
administering a combination of atezolizumab plus bevacizumab (AteBeva) compared to
sorafenib as first line systemic treatment for unresectable HCC was recently proven during
the IMbrave150 Phase III randomized trial. While clinicians can expect improved responses
and treatment outcomes due to the good results of the IMbrave 150 trial, they must also
consider that atezolizumab can cause various immune-related adverse events (IrAEs). Based
on the above suggestions, we herein present a case of HCC with lymph node metastasis
who achieved complete remission following treatment with AteBeva and developed an IrAE
(adrenal insufficiency). Further study of real-life data regarding combination therapy with
AteBeva is needed to manage patients with advanced HCC.
|
E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Follow JLC on Twitter